Early Oral Administration of D-Chiro-Inositol Reverses Hippocampal Insulin and Glutamate Signaling Deficits in the 3×Tg Humanized Mouse Model of Alzheimer’s Disease
Nutrients · 2025
DOI: 10.3390/nu17183024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Beatriz Pacheco-Sánchez und 12 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Neuropsicofarmacología, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Unidad Clínica…. Hauptthemen laut MEDLINE: Alzheimer Disease, Hippocampus, Insulin, Signal Transduction. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III. Proyectos de desarrollo tecnológico, Instituto de Salud Carlos III. Proyectos de Investigación en Salud, Instituto de Salud Carlos III (ISCIII).
Themen: Demenz
Abstract (Originalsprache)
Background and Objective: Humanized models of Alzheimer’s disease (AD) provide valuable tools for investigating the mechanisms of this neurodegenerative disorder, the leading cause of dementia. These models enable the study of AD progression and the potential disease-modifying properties of drugs or dietary nutrients delivered through nutrition. Here, we examine molecular markers of metabolic and synaptic dysfunction in the hippocampus of 6-month-old 3×Tg-AD mice and assess whether a dietary insulin sensitizer can delay synaptic decline.
Methods
First we characterized the molecular phenotype of 3×Tg-AD at 12 months using shotgun proteomics and phosphoproteomics to assess metabolic and synaptic changes in the hippocampus. Then, we characterized the effects of early daily oral D-chiro-inositol (DCI, Gyneos®) for three months, starting at 3 months of age, to test restoration of insulin signaling and glutamatergic synaptic markers. To this end we evaluated a) insulin signaling pathway components (insulin receptor, IRS1, PI3K, AKT, GSK3β) at mRNA, protein, and phosphorylation levels, and b) the expression of glutamate receptors (mGluR5, GluR1, GluR2, NMDAR1, NMDAR2A, NMDAR2B). Sex effects were explored.
Results
12-month 3×Tg-AD mice exhibit metabolic and synaptic dysfunction in the hippocampus, with phosphoproteomic changes suggesting altered glutamatergic synapses. At 6 months, disruptions in insulin signaling were evident, including altered expression and phosphorylation of insulin pathway components, and changes in glutamate receptor subunits. Early DCI treatment largely reversed these alterations. Several effects showed sex dependency.
Conclusions
Early insulin-sensitizing intervention via DCI can restore insulin signaling and counteract hippocampal synaptic impairments in this AD model, supporting the potential for nutrient-based strategies to delay synaptic decline. Sex differences underscore the need to tailor therapeutic approaches in modifying AD progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Grupo de Neuropsicofarmacología, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Unidad Clínica de Neurología, 29010 Málaga, Spain.
- Facultad de Ciencias, Universidad de Málaga, 29010 Málaga, Spain.
- Departamento de Anatomía Humana, Medicina Legal e Historia de la Ciencia, Facultad de Medicina, Universidad de Málaga, 29071 Málaga, Spain.
- Departamento de Bioquímica, Biología Molecular e Inmunología, Facultad de Medicina, Universidad de Málaga, 29010 Málaga, Spain.
- Andalusian Network for Clinical and Translational Research in Neurology [NEURO-RECA], 29001 Málaga, Spain.
- Euronutra S.L., Calle Johannes Kepler, 3, 29590 Málaga, Spain.
ORCID-Profile: Beatriz Pacheco-Sánchez, Miguel Rodríguez-Pozo, Juan A Navarro, Antonio J López-Gambero, Elena Baixeras, Juan Suárez, Carlos Sanjuan, Patricia Rivera, Fernando Rodríguez de Fonseca
Förderung
- Instituto de Salud Carlos III. Proyectos de desarrollo tecnológico
- Instituto de Salud Carlos III. Proyectos de Investigación en Salud
- Instituto de Salud Carlos III (ISCIII)
- Ministerio de Ciencia e Innovación—Agencia Estatal de Investigación
- Consejería de Salud y Consumo-Junta de Andalucía
- Partnership Fostering a European Research Area for Health (ERA4Health)
- Consejería de Universidad, Investigación e Innovación, Junta de Andalucía
- National System of Health, EU-ERDF-Instituto de Salud Carlos III
Zitieren
APA
Pacheco-Sánchez, B., Verheul-Campos, J., Vargas, A., Tovar, R., Rodríguez-Pozo, M., Navarro, J. A., López-Gambero, A. J., Baixeras, E., Serrano-Castro, P. J., Suárez, J., Sanjuan, C., Rivera, P., & Rodríguez de Fonseca, F. (2025). Early Oral Administration of D-Chiro-Inositol Reverses Hippocampal Insulin and Glutamate Signaling Deficits in the 3×Tg Humanized Mouse Model of Alzheimer’s Disease. Nutrients. https://doi.org/10.3390/nu17183024
Vancouver
Pacheco-Sánchez B, Verheul-Campos J, Vargas A, Tovar R, Rodríguez-Pozo M, Navarro JA, et al. Early Oral Administration of D-Chiro-Inositol Reverses Hippocampal Insulin and Glutamate Signaling Deficits in the 3×Tg Humanized Mouse Model of Alzheimer’s Disease. Nutrients. 2025. doi:10.3390/nu17183024
BibTeX
@article{PachecoSnchez2025,
author = {Pacheco-Sánchez, Beatriz and Verheul-Campos, Julia and Vargas, Antonio and Tovar, Rubén and Rodríguez-Pozo, Miguel and Navarro, Juan A and López-Gambero, Antonio J and Baixeras, Elena and Serrano-Castro, Pedro J and Suárez, Juan and Sanjuan, Carlos and Rivera, Patricia and Rodríguez de Fonseca, Fernando},
title = {Early Oral Administration of D-Chiro-Inositol Reverses Hippocampal Insulin and Glutamate Signaling Deficits in the 3×Tg Humanized Mouse Model of Alzheimer’s Disease},
journal = {Nutrients},
year = {2025},
doi = {10.3390/nu17183024}
}
EUVIMED